Potassium-competitive acid blockers and proton-pump inhibitors for the healing and maintenance of erosive esophagitis: a comprehensive and updated systematic review with network meta-analysis
- 1Department of Medicine, MetroHealth Medical Center, Case Western Reserve University, Cleveland, OH USA
- 2Division of Gastroenterology and Hepatology, The Esophageal and Swallowing Center, MetroHealth Medical Center, Case Western Reserve University, Cleveland, OH USA
Abstract
Randomized controlled trials (RCTs) suggest that potassium-competitive acid blockers (PCABs) are non-inferior to standard-dose proton pump inhibitors (PPIs) for erosive esophagitis (EE). However, direct comparative data against double-dose or dual-delayed release PPIs remain limited. This network meta-analysis (NMA) ranks the efficacy of PCABs and PPIs (standard, double, and dual-delayed-release doses) for EE healing and maintenance. A systematic search of MEDLINE, EMBASE, and the Cochrane Library from inception through February 2, 2025 (updated on December 15, 2025) identified RCTs comparing PCABs or PPIs in adults with endoscopically confirmed EE or previously healed EE. Primary outcomes were EE healing at weeks 4 and 8, and maintenance at 6 months. A frequentist NMA estimated risk ratios (RRs) with 95% confidence intervals (95%CI), using vonoprazan 20 mg once daily (QD) and 10 mg QD as reference for healing and maintenance studies, respectively; ranking metrics (P-scores) were used descriptively. A total of 99 RCTs were included. At week 4, several regimens showed similar healing rate to vonoprazan 20 mg QD, including linaprazan 75 mg BID, linaprazan 50 mg BID, and zastaprazan 20 mg QD. At week 8, zastaprazan 20 mg QD was significantly better than vonoprazan 20 mg QD (RR 1.10; 95%CI 1.01–1.21; P-score = 0.92). For maintenance at 6 months, several standard-dose regimens (including esomeprazole 40 mg QD and vonoprazan 20 mg QD) showed similar efficacy, whereas lower-dose PPIs performed worse. Adverse events were comparable across therapies. Zastaprazan 20 mg QD and esomeprazole 40 mg QD demonstrated the highest efficacy for EE healing and maintenance, respectively. Overall, PCABs did not consistently outperform dual-delayed release or double-dose PPIs.
Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s10388-026-01222-2.
Related
- The Clinical and Diagnostic Spectrum of Esophagitis Dissecans Superficialis: A Comprehensive Retrospective Case Series and Literature Review
- Comprehensive proteomic characterization of the esophageal String Test identifies a luminal protein signature associated with eosinophilic esophagitis.
- Maintenance of atrial fibrillation by reciprocal triggering of competitive focal sources: a hypothesis.
- Comparative efficacy and safety of dupilumab and swallowed topical corticosteroid formulations in eosinophilic esophagitis : A systematic review and network meta-analysis of randomized controlled trials
- Expectations for Angiopoietin-like 3 Inhibitors Taking Broad Lipid-modifying Effects on the Comprehensive Control of Atherosclerotic Cardiovascular Disease Risk in Patients with Homozygous Familial Hypercholesterolemia
BibTeX
@article{simadibrata2026potassiumcompetitive,
title = {{Potassium-competitive acid blockers and proton-pump inhibitors for the healing and maintenance of erosive esophagitis: a comprehensive and updated systematic review with network meta-analysis}},
author = {Daniel Martin Simadibrata and Thai Hau Koo and Raúl Alberto Jiménez-Castillo and Ronnie Fass},
journal = {Esophagus},
year = {2026},
month = jun,
doi = {10.1007/s10388-026-01222-2},
url = {https://doi.org/10.1007/s10388-026-01222-2},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Potassium-competitive acid blockers and proton-pump inhibitors for the healing and maintenance of erosive esophagitis: a comprehensive and updated systematic review with network meta-analysis
AU - Daniel Martin Simadibrata
AU - Thai Hau Koo
AU - Raúl Alberto Jiménez-Castillo
AU - Ronnie Fass
PY - 2026
DA - 2026/06/15
JO - Esophagus
DO - 10.1007/s10388-026-01222-2
UR - https://doi.org/10.1007/s10388-026-01222-2
AB - Randomized controlled trials (RCTs) suggest that potassium-competitive acid blockers (PCABs) are non-inferior to standard-dose proton pump inhibitors (PPIs) for erosive esophagitis (EE). However, direct comparative data against double-dose or dual-delayed release PPIs remain limited. This network meta-analysis (NMA) ranks the efficacy of PCABs and PPIs (standard, double, and dual-delayed-release doses) for EE healing and maintenance. A systematic search of MEDLINE, EMBASE, and the Cochrane Library from inception through February 2, 2025 (updated on December 15, 2025) identified RCTs comparing PCABs or PPIs in adults with endoscopically confirmed EE or previously healed EE. Primary outcomes were EE healing at weeks 4 and 8, and maintenance at 6 months. A frequentist NMA estimated risk ratios (RRs) with 95% confidence intervals (95%CI), using vonoprazan 20 mg once daily (QD) and 10 mg QD as reference for healing and maintenance studies, respectively; ranking metrics (P-scores) were used descriptively. A total of 99 RCTs were included. At week 4, several regimens showed similar healing rate to vonoprazan 20 mg QD, including linaprazan 75 mg BID, linaprazan 50 mg BID, and zastaprazan 20 mg QD. At week 8, zastaprazan 20 mg QD was significantly better than vonoprazan 20 mg QD (RR 1.10; 95%CI 1.01–1.21; P-score = 0.92). For maintenance at 6 months, several standard-dose regimens (including esomeprazole 40 mg QD and vonoprazan 20 mg QD) showed similar efficacy, whereas lower-dose PPIs performed worse. Adverse events were comparable across therapies. Zastaprazan 20 mg QD and esomeprazole 40 mg QD demonstrated the highest efficacy for EE healing and maintenance, respectively. Overall, PCABs did not consistently outperform dual-delayed release or double-dose PPIs. Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s10388-026-01222-2.
SN - 1612-9059
SN - 1612-9067
ER -